Primary intraocular lymphoma: An international primary central nervous system lymphoma collaborative group report

S. A. Grimm, J. S. Pulido, K. Jahnke, D. Schiff, A. J. Hall, T. N. Shenkier, T. Siegal, Nancy Doolittle, T. Batchelor, U. Herrlinger, Edward Neuwelt, N. Laperriere, M. C. Chamberlain, J. Y. Blay, A. J M Ferreri, A. M P Omuro, E. Thiel, L. E. Abrey

Research output: Contribution to journalArticle

111 Citations (Scopus)

Abstract

Background: Primary intraocular lymphoma (PIOL) is an uncommon subset of primary central nervous system lymphoma. Because it is rare and difficult to diagnose, the natural history and optimal management are unknown. Patients and methods: A retrospective study of 83 HIV negative, immunocompetent PIOL patients was assembled from 16 centers in seven countries. Results: Median age at diagnosis was 65. Median ECOG performance status was 0. Presenting symptoms included blurred vision, decreased visual acuity, and floaters. Median time to diagnosis was 6 months. Diagnosis was made by vitrectomy (74), choroidal/retinal biopsy (6) and ophthalmic exam (3). Eleven percent had positive CSF cytology. Initial treatment was categorized as focal in 23 (intra-ocular methotrexate, ocular radiotherapy) or extensive in 53 (systemic chemotherapy, whole brain radiotherapy). Six received none; details are unknown in one. Forty-seven relapsed: brain 47%, eyes 30%, brain and eyes 15%, and systemic 8%. Median time to relapse was 19 months. Focal therapy alone did not increase risk of brain relapse. Median progression free (PFS) and overall survival (OS) were 29.6 and 58 months, respectively, and unaffected by treatment type. Conclusion: Treatment type did not affect relapse pattern, median PFS or OS. Focal therapy may minimize treatment toxicity without compromising disease control.

Original languageEnglish (US)
Pages (from-to)1851-1855
Number of pages5
JournalAnnals of Oncology
Volume18
Issue number11
DOIs
StatePublished - Nov 2007

Fingerprint

Intraocular Lymphoma
Lymphoma
Central Nervous System
Brain
Recurrence
Radiotherapy
Therapeutics
Survival
Vitrectomy
Natural History
Methotrexate
Visual Acuity
Cell Biology
Retrospective Studies
HIV
Biopsy
Drug Therapy

Keywords

  • Ocular lymphoma
  • Primary CNS lymphoma

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Grimm, S. A., Pulido, J. S., Jahnke, K., Schiff, D., Hall, A. J., Shenkier, T. N., ... Abrey, L. E. (2007). Primary intraocular lymphoma: An international primary central nervous system lymphoma collaborative group report. Annals of Oncology, 18(11), 1851-1855. https://doi.org/10.1093/annonc/mdm340

Primary intraocular lymphoma : An international primary central nervous system lymphoma collaborative group report. / Grimm, S. A.; Pulido, J. S.; Jahnke, K.; Schiff, D.; Hall, A. J.; Shenkier, T. N.; Siegal, T.; Doolittle, Nancy; Batchelor, T.; Herrlinger, U.; Neuwelt, Edward; Laperriere, N.; Chamberlain, M. C.; Blay, J. Y.; Ferreri, A. J M; Omuro, A. M P; Thiel, E.; Abrey, L. E.

In: Annals of Oncology, Vol. 18, No. 11, 11.2007, p. 1851-1855.

Research output: Contribution to journalArticle

Grimm, SA, Pulido, JS, Jahnke, K, Schiff, D, Hall, AJ, Shenkier, TN, Siegal, T, Doolittle, N, Batchelor, T, Herrlinger, U, Neuwelt, E, Laperriere, N, Chamberlain, MC, Blay, JY, Ferreri, AJM, Omuro, AMP, Thiel, E & Abrey, LE 2007, 'Primary intraocular lymphoma: An international primary central nervous system lymphoma collaborative group report', Annals of Oncology, vol. 18, no. 11, pp. 1851-1855. https://doi.org/10.1093/annonc/mdm340
Grimm, S. A. ; Pulido, J. S. ; Jahnke, K. ; Schiff, D. ; Hall, A. J. ; Shenkier, T. N. ; Siegal, T. ; Doolittle, Nancy ; Batchelor, T. ; Herrlinger, U. ; Neuwelt, Edward ; Laperriere, N. ; Chamberlain, M. C. ; Blay, J. Y. ; Ferreri, A. J M ; Omuro, A. M P ; Thiel, E. ; Abrey, L. E. / Primary intraocular lymphoma : An international primary central nervous system lymphoma collaborative group report. In: Annals of Oncology. 2007 ; Vol. 18, No. 11. pp. 1851-1855.
@article{5078d18ca702449caa39e820c61f3cef,
title = "Primary intraocular lymphoma: An international primary central nervous system lymphoma collaborative group report",
abstract = "Background: Primary intraocular lymphoma (PIOL) is an uncommon subset of primary central nervous system lymphoma. Because it is rare and difficult to diagnose, the natural history and optimal management are unknown. Patients and methods: A retrospective study of 83 HIV negative, immunocompetent PIOL patients was assembled from 16 centers in seven countries. Results: Median age at diagnosis was 65. Median ECOG performance status was 0. Presenting symptoms included blurred vision, decreased visual acuity, and floaters. Median time to diagnosis was 6 months. Diagnosis was made by vitrectomy (74), choroidal/retinal biopsy (6) and ophthalmic exam (3). Eleven percent had positive CSF cytology. Initial treatment was categorized as focal in 23 (intra-ocular methotrexate, ocular radiotherapy) or extensive in 53 (systemic chemotherapy, whole brain radiotherapy). Six received none; details are unknown in one. Forty-seven relapsed: brain 47{\%}, eyes 30{\%}, brain and eyes 15{\%}, and systemic 8{\%}. Median time to relapse was 19 months. Focal therapy alone did not increase risk of brain relapse. Median progression free (PFS) and overall survival (OS) were 29.6 and 58 months, respectively, and unaffected by treatment type. Conclusion: Treatment type did not affect relapse pattern, median PFS or OS. Focal therapy may minimize treatment toxicity without compromising disease control.",
keywords = "Ocular lymphoma, Primary CNS lymphoma",
author = "Grimm, {S. A.} and Pulido, {J. S.} and K. Jahnke and D. Schiff and Hall, {A. J.} and Shenkier, {T. N.} and T. Siegal and Nancy Doolittle and T. Batchelor and U. Herrlinger and Edward Neuwelt and N. Laperriere and Chamberlain, {M. C.} and Blay, {J. Y.} and Ferreri, {A. J M} and Omuro, {A. M P} and E. Thiel and Abrey, {L. E.}",
year = "2007",
month = "11",
doi = "10.1093/annonc/mdm340",
language = "English (US)",
volume = "18",
pages = "1851--1855",
journal = "Annals of Oncology",
issn = "0923-7534",
publisher = "Oxford University Press",
number = "11",

}

TY - JOUR

T1 - Primary intraocular lymphoma

T2 - An international primary central nervous system lymphoma collaborative group report

AU - Grimm, S. A.

AU - Pulido, J. S.

AU - Jahnke, K.

AU - Schiff, D.

AU - Hall, A. J.

AU - Shenkier, T. N.

AU - Siegal, T.

AU - Doolittle, Nancy

AU - Batchelor, T.

AU - Herrlinger, U.

AU - Neuwelt, Edward

AU - Laperriere, N.

AU - Chamberlain, M. C.

AU - Blay, J. Y.

AU - Ferreri, A. J M

AU - Omuro, A. M P

AU - Thiel, E.

AU - Abrey, L. E.

PY - 2007/11

Y1 - 2007/11

N2 - Background: Primary intraocular lymphoma (PIOL) is an uncommon subset of primary central nervous system lymphoma. Because it is rare and difficult to diagnose, the natural history and optimal management are unknown. Patients and methods: A retrospective study of 83 HIV negative, immunocompetent PIOL patients was assembled from 16 centers in seven countries. Results: Median age at diagnosis was 65. Median ECOG performance status was 0. Presenting symptoms included blurred vision, decreased visual acuity, and floaters. Median time to diagnosis was 6 months. Diagnosis was made by vitrectomy (74), choroidal/retinal biopsy (6) and ophthalmic exam (3). Eleven percent had positive CSF cytology. Initial treatment was categorized as focal in 23 (intra-ocular methotrexate, ocular radiotherapy) or extensive in 53 (systemic chemotherapy, whole brain radiotherapy). Six received none; details are unknown in one. Forty-seven relapsed: brain 47%, eyes 30%, brain and eyes 15%, and systemic 8%. Median time to relapse was 19 months. Focal therapy alone did not increase risk of brain relapse. Median progression free (PFS) and overall survival (OS) were 29.6 and 58 months, respectively, and unaffected by treatment type. Conclusion: Treatment type did not affect relapse pattern, median PFS or OS. Focal therapy may minimize treatment toxicity without compromising disease control.

AB - Background: Primary intraocular lymphoma (PIOL) is an uncommon subset of primary central nervous system lymphoma. Because it is rare and difficult to diagnose, the natural history and optimal management are unknown. Patients and methods: A retrospective study of 83 HIV negative, immunocompetent PIOL patients was assembled from 16 centers in seven countries. Results: Median age at diagnosis was 65. Median ECOG performance status was 0. Presenting symptoms included blurred vision, decreased visual acuity, and floaters. Median time to diagnosis was 6 months. Diagnosis was made by vitrectomy (74), choroidal/retinal biopsy (6) and ophthalmic exam (3). Eleven percent had positive CSF cytology. Initial treatment was categorized as focal in 23 (intra-ocular methotrexate, ocular radiotherapy) or extensive in 53 (systemic chemotherapy, whole brain radiotherapy). Six received none; details are unknown in one. Forty-seven relapsed: brain 47%, eyes 30%, brain and eyes 15%, and systemic 8%. Median time to relapse was 19 months. Focal therapy alone did not increase risk of brain relapse. Median progression free (PFS) and overall survival (OS) were 29.6 and 58 months, respectively, and unaffected by treatment type. Conclusion: Treatment type did not affect relapse pattern, median PFS or OS. Focal therapy may minimize treatment toxicity without compromising disease control.

KW - Ocular lymphoma

KW - Primary CNS lymphoma

UR - http://www.scopus.com/inward/record.url?scp=36148956203&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=36148956203&partnerID=8YFLogxK

U2 - 10.1093/annonc/mdm340

DO - 10.1093/annonc/mdm340

M3 - Article

C2 - 17804469

AN - SCOPUS:36148956203

VL - 18

SP - 1851

EP - 1855

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

IS - 11

ER -